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A B S T R A C T
Background
Postpartum constipation, with symptoms such as pain or discomfort, straining, and hard stool, is a common condition affecting
mothers. Haemorrhoids, pain at the episiotomy site, effects of pregnancy hormones and haematinics used in pregnancy can increase
the risk of postpartum constipation. Eating a high-fibre diet and increasing fluid intake is usually encouraged, although laxatives are
commonly used in relieving constipation. The effectiveness and safety of available interventions for preventing postpartum constipation
needs to be ascertained.
Objectives
To evaluate the effectiveness and safety of interventions for preventing postpartum constipation.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (30 April 2015), Stellenbosch University database,
ProQuest Dissertation and Theses database, World Health Organization International Clinical Trials Registry Platform (ICTRP),
ClinicalTrials.gov (30 April 2015) and reference lists of included studies.
Selection criteria
All randomised controlled trials (RCTs) comparing any intervention for preventingpostpartumconstipation versus another intervention,
placebo or no intervention. Interventions could include pharmacological (e.g. laxatives) and non-pharmacological interventions (e.g.
acupuncture, educational and behavioural interventions).
We included quasi-randomised trials. Cluster-RCTs were eligible for inclusion but none were identified. Studies using a cross-over
design were not eligible for inclusion in this review.
Data collection and analysis
Two review authors independently screened the results of the search to select potentially relevant studies, extracted data and assessed
risk of bias. Results were pooled in a meta-analysis only where there was no substantial statistical heterogeneity.
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Main results
We included five trials (1208 postpartum mothers); four compared a laxative with placebo and one compared a laxative alone versus the
same laxative plus a bulking agent in women who underwent surgical repair of third degree perineal tears. Trials were poorly reported
and risk of bias was unclear for most domains. Overall, there was a high risk of selection and attrition bias.
Laxative versus placebo
None of the four trials included in this comparison assessed any of our pre-specified primary outcomes (pain or straining on defecation,
incidence of postpartum constipation or changes in quality of life).
All four trials reported time to first bowel movement (not pre-specified in our protocol). In one trial, more women in the laxative
group had their first bowel movement less than 24 hours after delivery compared to women in the placebo group (risk ratio (RR) 2.90,
95% confidence interval (CI) 2.24 to 3.75, 471 women). Individual trials also reported inconsistent results for days one, two and three
after delivery. Pooled results of two trials showed that fewer women in the laxative group were having their first bowel movement at
day four compared with controls (average RR 0.36, 95% CI 0.21 to 0.61, 671 women).
Regarding secondary outcomes, no trials reported on stool consistency using the Bristol stool form scale orrelief of abdominal
pain/discomfort . One trial reported the number of women having loose or watery stools and there were more women who experienced
this in the laxative group compared to the placebo group (RR 26.96, 95% CI 3.81 to 191.03, 106 women). One trial found no clear
difference in the number of enemas between groups (RR 0.63, 95% CI 0.38 to 1.05, 244 women). One trial reported more women
having more than two bowel movements per day in the laxative compared to the placebo group (RR 26.02, 95% CI 1.59 to 426.73,
106 women).
Adverse effects were poorly reported; two trials reported the number of women having abdominal cramps, but their results could not
be pooled in a meta-analysis due to substantial statistical heterogeneity. In one trial, more women in the laxative group had abdominal
cramps compared to the placebo group (RR 4.23, 95% CI 1.75 to 10.19, 471 women), while the other trial showed no difference
between groups (RR 0.25, 95% CI 0.03 to 2.20, 200 women). With regards to adverse effects of the intervention on the baby , one
trial found no difference in the incidence of loose stools (RR 0.62, 95% CI 0.16 to 2.41, 281 women) or diarrhoea (RR 2.46, 95% CI
0.23 to 26.82, 281 women) between the two groups.
Laxative versus laxative plus bulking agent
Only one trial was included in this comparison and reported on pain or straining on defecation in women who underwent surgical
repair of third degree perineal tears; there was no reported difference between groups (median (range) data only). No difference
was reported in the incidence of postpartum constipation (data not reported) and the outcome changes in quality of life was not
mentioned.Time to first bowel movement was reported as a median (range) with no difference between the two groups. In terms of
adverse effects , women in the laxative plus stool-bulking group were reported to be at a greater risk of faecal incontinence during the
immediate postpartum period (median (range) data only). However the number of women having any episode of faecal incontinence
during first 10 days postpartum was reported with no clear difference between the two groups (14/77 (18.2%) versus 23/70 (32.9%),
RR 0.55, 95% CI 0.31 to 0.99, 147 women). The trial did not report on adverse effects of the intervention on the babies.
The trial reported none of the following pre-specified secondary outcomes: stool consistency using Bristol stool form scale , use of
alternative products , laxative agents , enemas , relief of abdominal pain/discomfort and stool frequency .
Authors’ conclusions
We did not identify any trials assessing educational or behavioural interventions. We identified four trials that examined laxatives versus
placebo and one that examined laxatives versus laxatives plus stool bulking agents. Results from trials were inconsistent and there is
insufficient evidence to make general conclusions about the effectiveness and safety of laxatives.
Further rigorous trials are needed to assess the effectiveness and safety of laxatives during the postpartum period for preventing
constipation. Trials assessing educational and behavioural interventions and positions that enhance defecation are also needed. Future
trials should report on the following important outcomes: pain or straining on defecation; incidence of postpartum constipation, quality
of life, time to first bowel movement after delivery, and adverse effects caused by the intervention such as: nausea or vomiting, pain
and flatus.
P L A I N L A N G U A G E S U M M A R Y
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Interventions for preventing constipation after giving birth
Constipation is a bowel disorder that is characterised by symptoms such as pain or discomfort, straining, hard lumpy stool and a sense of
incomplete bowel evacuation. Pain and discomfort during defecation can be a source of concern to the new mother who is recuperating
from the stress of delivery, particularly if she has had perineal tears repaired or has developed haemorrhoids. Postpartum constipation
can be stressful for women because of undue pressure on the rectal wall, leading to restlessness and painful bowel movements which
may affect the quality of life of the mother. The administration of enemas before labour, the ability of women to eat during active
labour, and irregular and altered eating habits during the first few days after delivery can each have an influence on bowel movements
in the days after giving birth. We aimed to find all the trials assessing interventions that could prevent postpartum constipation. We
examined the available evidence up to 30 April 2015. We included five randomised controlled trials (involving a total of 1208 women
from the first day of giving birth) in this review. Overall, the trials were poorly conducted and reported.
Four trials compared a laxative with a placebo control. The trials did not look at pain or straining on defecation, incidence of constipation,
or changes in the quality of life, but did assess the time to first bowel movement. More women in the laxative group had a bowel
movement on the day of delivery in one trial. For days one, two and three after the birth, the findings from the trials were not consistent.
Combined results of two trials found that more women in the placebo group had their first bowel movement bowel four days after
delivery compared to the laxative group. Adverse effects of the intervention were poorly reported in the trials. Two trials reported on
abdominal cramps but we were unable to combine the results of the two trials because they were very different (one study found more
women had abdominal cramps compared to the women in the placebo control group whereas the other study found no difference
between groups). In terms of adverse effects of the intervention for the baby, one trial found that babies whose mothers received laxative
were no more likely to experience loose stool or diarrhoea.
One trial compared a laxative with a laxative plus a stool-bulking agent (Ispaghula husk) for women who underwent surgery to repair
a tear of the perineum involving the internal or external anal sphincter muscles (third degree) that occurred during vaginal delivery.
The trial reported on pain or straining on defecation but did not find a difference in the pain score between groups. In terms of
adverse effects of the intervention, the trial reported that women who were given laxative plus a stool-bulking agent were more likely to
experience fecal incontinence during the immediate postpartum period. However the number of women having any episode of faecal
incontinence during first 10 days postpartum was reported with no clear difference between the laxative and the laxative plus stool-
bulking agent group (14/77 (18.2%) versus 23/70 (32.9%), 147 women). This trial reported no data in relation to any adverse effects
that the intervention might have on the baby.
There is not enough evidence from randomised controlled trials on the effectiveness and safety of laxatives during the early postpartum
period to make general conclusions about their use to prevent constipation. We did not identify any trials assessing educational or
behavioural interventions such as a high-fibre diet and exercise.
We found some evidence that adding a stool-bulking agent to a laxative for women who underwent surgery to repair a third degree
perineal tear is not beneficial. Large, high-quality trials are needed on this topic. In addition, trials looking at non-medical interventions,
such as advice on diet and physical activity, are needed.
B A C K G R O U N D
Description of the condition
The postpartum period comprises the first six weeks after delivery
during which the mother’s body returns to the pre-pregnant state
(Liu 2009). It is a critical transitional time for the new mother,
her newborn baby and her family. Many complications can occur
during this period and if unrecognised and not treated promptly,
may lead to physical discomfort, psychological distress, low self-es-
teem and poor quality of life for themother (Zainur 2006). There-
fore, adequate attention, appropriate advice and services need to
be available to mothers during this period in order to prevent post-
natal health problems as well as detect medical complications at
an early stage (World Health Organization 1998).
Constipation can be defined as difficult bowel evacuation char-
acterised by straining, lumpy or hard and dry stools, sensation
of incomplete evacuation, anorectal obstruction, or manual ma-
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noeuvres (Higgins 2004). It is a functional bowel disorder and
a common health problem across all ages and a source of con-
cern during pregnancy, the postpartum period and after surgery
(National Institute of Health 2013). The diagnosis of constipation
is both subjective and objective, however, according to the Rome
diagnostic criteria III (Drossman 2006), a diagnosis of functional
constipation needs to include two of the following criteria, which
must be fulfilled for the last three months with symptom onset at
least six months prior to diagnosis: straining during at least 25 %
of defecations, lumpy or hard stools in at least 25% of defecations,
sensation of incomplete evacuation for at least 25% of defecations,
sensation of anorectal obstruction/blockage for at least 25% of
defecations, manual manoeuvres to facilitate at least 25% of defe-
cations (e.g. digital evacuation, support of the pelvic floor), fewer
than three defecations per week; and loose stools are rarely present
without the use of laxatives (Lee-Robichaud 2010).
Globally, constipation is common to all ages and the prevalence
was estimated to lie between 4.1% and 25.6% in studies using the
self-report measure of constipation and between 2.6% and 26.9%
in those using the Rome criteria (Schmidt 2014); it is higher in
the non-white population than in the white population (Gandell
2013; Stewart 1992; Towers 1994). It was reported that constipa-
tion is more prevalent in women (37%) than in men (14%), and
that low-income and individuals with a low socio-economic status
are at higher risk of constipation (Collete 2010). The prevalence of
postpartum constipation was reported to be 41.8% by self-report
and 24.7% as classified by the Rome criteria (Ponce 2008); and
that 25% of women suffer from constipation throughout preg-
nancy and at three months postpartum (Bradley 2007). Further-
more, an association between defecation symptoms in early preg-
nancy (12 weeks’ gestation) in women with lower body mass in-
dex (BMI) and constipation at 12 months after childbirth was re-
ported by Van Brummen 2006. A study reported that having two
or fewer bowel movements a week is thought to occur in one third
of women in their third trimester of pregnancy (Wald 2003).
Postpartum constipation is characterised by symptoms such as ab-
dominal pain or discomfort, excessive straining, hard stool that is
difficult to pass, lumpy stool and a sensation of incomplete evac-
uation (Cullen 2007). Constipation in the postpartum period is
thought to be caused by the high progesterone levels during preg-
nancy and interruption in dietary intake (Glazener 1995). Haem-
orrhoids are a frequent anorectal ailment in pregnancy and in the
postpartumperiod. Fear of expected pain from swelling at the anus
as a result of haemorrhoids, pain at the episiotomy site, a bruised
perineum and lacerations in the vagina may contribute to post-
partum constipation. Haematinics (agents used to stimulate blood
cell formation or to increase the haemoglobin in the blood) used
in pregnancy (Bradley 2007), reduced physical activity following
delivery, ignoring the urge to move the bowel and diets low in
fibre may increase the risk of developing postpartum constipation
(National Institute of Health 2013). During the postpartum pe-
riod, not only is pain from constipation a discomfort to the new
mother, it may also impact on her physical and social health sta-
tus and may hinder timely response to the needs of the newborn
(Cheng 2006).
Description of the intervention and how the
intervention might work
Agoodunderstanding of the causes of constipation can help in pre-
venting and averting problems that are associated with constipa-
tion. Constipation occurs when the stool stays in the colon longer
than expected and the colon absorbs too much water from the
stool, thus making the stool hard and dry and therefore, difficult
to pass (National Institute of Health 2013). The interventions for
preventing constipation include pharmacological and non-phar-
macological interventions. Lifestyle interventions refer to diet and
physical exercise and are advocated during pregnancy and the post-
partum period. A diet high in fibre and adequate fluid intake may
be all that is required for prevention of postpartum constipation
(Zainur 2006). High-fibre foods such as fruits and vegetables can
help to relieve symptoms and prevent constipation in the post-
partum period (Liu 2009). Fibre is indigestible, adds bulk to the
stools and stimulates bowel movements, and it also improves di-
gestion and prevents constipation by softening the stools (Balch
2010). Gradual resumption of physical exercise that is medically
safe should be encouraged as soon as the mother becomes fit for
exercise. This time-point varies from one individual to another
with some women able to resume routine exercise within days of
delivery (Koltyn 1997).
For pharmacological interventions, laxatives are the drugs of choice
in relieving symptoms of constipation and can be taken orally in
either liquid, tablet, powder or granule form. Laxatives are grouped
into categories according to their mode of action: bulk forming
laxatives, osmotic laxatives, stimulant laxatives, faecal softeners
and lubricants (Candy 2011). Bulk forming laxatives, such as bran
and methylcellulose, increase the weight and water content and
facilitate peristaltic movement of stools (Balch 2010). Osmotic
laxatives, such asMilk ofMagnesia and lactulose, help retain water
in the colon thereby softening the stool and increasing the number
of stools (National Institute of Health 2013). Stimulant laxatives,
such as bisacodyl and senna, directly stimulate the afferent nerves
and irritate the intestinal wall thereby easing bowel movement
(Andrew 2011). Stimulant laxatives are useful when constipation
is not responsive to osmotic laxatives (Balch 2010).
Alternative interventions for constipation also exist. Studies have
reported on the efficacy of acupuncture and Chinese herbal
medicine as an intervention in the prevention of postpartum con-
stipation. Chinese herbs reportedly work by correcting the under-
lying malfunctions through strengthening the intestinal tract, and
thereby improving peristalsis. The Yun-chang capsule, a Chinese
herb capsule, was found to be effective and safe for the treatment
of patients with functional constipation (Jia 2009), while a sys-
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tematic review reported an overall significant benefit of traditional
Chinese medicine in relieving constipation (Lin 2009).
Why it is important to do this review
The postpartum period is a crucial time for the new mother, new-
born baby and the entire family. A number of health problems
may occur during this period that may result in physical discom-
fort and poor quality of life for the mother and the baby. Accord-
ing to Peppas 2008, constipation has a significant negative impact
on the quality of life, in terms of morbidity and cost of treat-
ment. A number of systematic reviews on interventions for con-
stipation have been published (e.g. Gordon 2012; Higgins 2004;
Lee-Robichaud 2010; Mugie 2011; Peppas 2008). We recently
conducted a Cochrane review on interventions for treating post-
partum constipation (Turawa 2014). We did not find any trials
eligible for inclusion, but some of the excluded trials assessed in-
terventions for the prevention of constipation. To our knowledge,
there is no systematic review on preventing postpartum consti-
pation and considering the debilitating effect of constipation on
the new mother and her baby, and the financial implications, it
is necessary to assess the effectiveness and safety of the available
interventions for preventing postpartum constipation.
O B J E C T I V E S
Toassess the safety and effectiveness of interventions for preventing
postpartum constipation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials comparing any in-
tervention for the prevention of postpartum constipation with an-
other intervention, placebo or no intervention. Quasi-randomised
controlled trials were included. Cluster-randomised trials were eli-
gible for inclusion but none were identified. Cross-over trials were
not eligible for inclusion because the physiological condition of
women during the first month postpartum might not be the same
as at six months after childbirth.
Types of participants
We included all postpartum women (up to six months post deliv-
ery) with symptoms of postpartum constipation using pre-spec-
ified criteria (Rome and Bristol Stool Form Scale) and self-re-
port. Postpartum women with co-morbidities, such as sphincter
injuries, were included. The six months criterion was used because
constipation is a problem that may last longer than six weeks fol-
lowing delivery, which is the usual postpartum period.
Types of interventions
Intervention
Any intervention for the prevention of postpartum constipation,
both pharmacological (e.g. laxatives) and non-pharmacological in-
terventions (e.g. acupuncture, educational and behavioural inter-
ventions).
Control
Any other intervention for the prevention of postpartum consti-
pation, placebo or no intervention.
We considered the following comparisons.
1. One intervention versus no intervention
2. One intervention versus placebo
3. Two different interventions compared
4. One intervention versus a combination of interventions
5. Combination of interventions versus no intervention
6. Combination of interventions versus placebo
7. Different combinations of interventions
Types of outcome measures
Primary outcomes
1. Pain or straining on defecation
2. Incidence of postpartum constipation as per self-report and
other diagnostic criteria
3. Changes in quality of life as measured in included studies
(using e.g. maternal postpartum quality of life (MAPP-QOL)
questionnaire)
4. Time to first bowel movement (days) (outcome not pre-
specified at the protocol stage - see Differences between protocol
and review)
Secondary outcomes
1. Stool consistency using Bristol stool form scale. Appendix
1. The Bristol Stool Form Scale is a formal research tool that is
used to categorise stool into seven criteria according to stool
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consistency (Lewis 1997). It is also useful for evaluating the
effectiveness of intervention for gastrointestinal tract disease and
clinical assessment. It helps patients to report on stool
consistency.
2. Use of alternative products, laxative agents, enemas.
3. Relief of abdominal pain/discomfort.
4. Stool frequency.
5. Adverse effects caused by the intervention, including:
i) pain;
ii) nausea and vomiting;
iii) diarrhoea, flatus, and faecal incontinence.
6. Any adverse effects of the intervention on the baby.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (30
April 2015).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
In addition, we searched the Stellenbosch University database,
ProQuest Dissertation and Theses database, and the following
sources.
1. The US National Institutes of Health Ongoing Trials
Register (ClinicalTrials.gov).
2. The World Health Organization International Clinical
trials Registry platform (ICTRP).
Searched carried out on 30 April 2015. See: Appendix 2 for search
terms used.
Searching other resources
We checked the reference list of retrieved studies for additional
studies and contacted authors and experts in the field.
We did not apply any language or date restrictions.
Data collection and analysis
Selection of studies
Two review authors (Eunice Turawa (ET) and Alfred Musekiwa
(AM) ) independently assessed for inclusion all the potential stud-
ies we identified from the searches. We resolved any disagreement
through discussion or, if required, we consulted the third review
author (Anke Rohwer (AR)).
We developed a Preferred Reporting Items for Systematic Reviews
andMeta-analyses (PRISMA) study flow chart to display the num-
ber of records identified, included and excluded from the review
(Liberati 2009).
Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors (ET and AM) extracted the data using the data extraction
form. For each dichotomous outcome, we extracted the number
of participants experiencing the event and the number of partici-
pants in each treatment group. For each continuous outcome, we
planned to extract the arithmetic means and standard deviations
(or information to estimate the standard deviations). We resolved
discrepancies through discussion or, if required, we consulted the
third author (AR).We entered data into ReviewManager software
(RevMan 2014) and checked for accuracy. When information re-
garding any of the above was unclear, we attempted to contact
authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors (ET and AM) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreement by discussion or by involving a third
review author (AR).
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
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We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received.We considered that studies are
at low risk of bias if they were blinded, or if we judge that the
lack of blinding would be unlikely to affect results. We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we re-included missing data in the analyses
which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation). Attrition bias of 20% and above were
considered as high risk of bias;
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
Wemade explicit judgements aboutwhether studies are at high risk
of bias, according to the criteria given in the Handbook (Higgins
2011). With reference to (1) to (6) above, we assessed the likely
magnitude and direction of the bias and whether we consider it is
likely to impact on the findings.We explored the impact of the level
of bias through undertaking sensitivity analyses - see Sensitivity
analysis.
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The results were summarised using the ’Risk of bias’ summary and
the ’Risk of bias’ graph in addition to the ’Risk of bias’ tables.
Where clarity was required or in case of missing data, we contacted
the trial authors for clarification. We resolved any disagreement
by discussion.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we planned to use the mean difference if
outcomesweremeasured in the sameway between trials.Wewould
have used the standardised mean difference to combine trials that
measured the same outcome, but used differentmethods. In either
case, corresponding 95% confidence intervals would have been
presented.
Unit of analysis issues
There were no unit of analysis issues as only individually-ran-
domised trials were included.
Cluster-randomised trials
We did not identify any cluster-randomised trials for inclusion
in this review. However, in future updates of this review, if we
identify any cluster-randomised trials we will include them in the
analyses along with individually-randomised trials. We will adjust
their sample sizes using the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions Section 16.3.4 (
Higgins 2011), using an estimate of the intracluster correlation co-
efficient (ICC) derived from the trial (if possible), from a similar
trial or from a study of a similar population. If we use ICCs from
other sources, we will report this and conduct sensitivity analyses
to investigate the effect of variation in the ICC. If we identify both
cluster-randomised trials and individually-randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
the effect of intervention and the choice of randomisation unit is
considered to be unlikely. We will also acknowledge heterogene-
ity in the randomisation unit and perform a subgroup analysis to
investigate the effects of the randomisation unit.
Other unit of analysis issues
In future studies, if a multi-arm study contributes multiple com-
parisons to a particularmeta-analysis, wewill either combine treat-
ment groups or split the ‘shared’ group as appropriate and precau-
tions will be taken to avoid the inclusion of data from the same
participant more than once in the same analysis.
Dealing with missing data
No imputation measures were applied for missing data. Where
data from the trial reports were insufficient, unclear or missing,
we contacted the trial authors by email for additional information
or clarification. For included trials, we took note of the level of
attrition.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we included all participants ran-
domised to each group in the analyses, and all participants were
analysed in the group to which they were allocated, regardless of
whether or not they received the allocated intervention. The de-
nominator for each outcome in each trial was the number ran-
domised, minus any participants whose outcomes were known to
be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial where an I² was greater than 30% and either a T² was
greater than zero, or there was a low P value (less than 0.10) in the
Chi² test for heterogeneity.
Assessment of reporting biases
In future updates of this review, if there are 10 or more studies
in the meta-analysis we will investigate reporting biases (such as
publication bias) using funnel plots. We will assess funnel plot
asymmetry visually. If asymmetry is suggested by a visual assess-
ment, we will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014). Where there was clinical heterogeneity suf-
ficient to expect that the underlying treatment effects differed be-
tween trials, or substantial statistical heterogeneity was detected,
we did not pool trial results in a meta-analysis. In cases where
statistical heterogeneity was not substantial we used random-ef-
fects meta-analysis to produce an overall summary, if an average
treatment effect across trials was considered clinically meaningful.
The random-effects summary was treated as the average range of
possible treatment effects and we discussed the clinical implica-
tions of treatment effects differing between trials. Where the av-
erage treatment effect was not clinically meaningful, we did not
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combine trials.Where we used random-effects analyses, the results
were presented as the average treatment effect with 95% confi-
dence intervals, and the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
We were not able to conduct subgroup analysis in this review
since the meta-analyses performed had very few trials. For future
updates, wewill use subgroup analyses to investigate heterogeneity.
We will carry out the following subgroup analyses.
1. Type of laxatives (osmotic laxatives versus stimulant
laxatives; bulk forming laxatives versus stimulant laxatives)
2. Study design (individually-randomised versus cluster-
randomised trials)
3. Mode of delivery (caesarean section versus spontaneous
vaginal delivery)
We will limit these subgroup analyses to the primary outcomes of
the review.
We will assess subgroup differences by interaction tests available
within RevMan (Higgins 2011). We will report the results of sub-
group analyses quoting the X2 statistic and P value, and the inter-
action test I² value.
Sensitivity analysis
We were not able to conduct sensitivity analysis in this review
since the meta-analyses performed had very few trials. For future
updates of the review, we will perform sensitivity analysis with
respect to:
1. robustness of the methods used regarding allocation
concealment;
2. rates of attrition;
3. imputed values of intra-cluster correlations (ICC).
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
The search of Cochrane Pregnancy and Childbirth Group’s Tri-
als Register retrieved seven trial reports. The Stellenbosch Univer-
sity database; ProQuest Dissertation and Theses database search
yielded one additional trial making a total of eight reports. We ex-
cluded two trials (Liu 2009;Mahony 2004) (published in three re-
ports) with reasons reported in Characteristics of excluded studies.
We includedfive trials in this review (Diamond 1968; Eogan 2007;
Mundow 1975; Shelton 1980; Zuspan 1960). See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Details of the included studies are provided in the Characteristics
of included studies We included five trials with a total of 1208
participants. Of the five included trials, three are randomised con-
trolled trials (Diamond 1968; Eogan 2007; Shelton 1980) and
two trial records are quasi-randomised controlled trials (Mundow
1975; Zuspan 1960). Four of the trials were from developed coun-
tries (Diamond 1968 ; Eogan 2007; Mundow 1975 and Zuspan
1960), while the fifth trial was from a developing country (Shelton
1980). All trials were conducted in a tertiary institution and the
unit of randomisation for all trials was the individual. Trials were
published in English language, four of the trials compared a phar-
maceutical intervention (laxative) with a placebo, while the fifth
trial compared a laxative with a bulking-agent plus the same laxa-
tive in the prevention of postpartum constipation. The drugs used
in three of the trials (Diamond 1968; Shelton 1980 and Zuspan
1960) were supplied by pharmaceutical companies and the statis-
tical analysis of Shelton 1980 was carried out by the same com-
pany that provided the drug. None of the trials discussed conflicts
of interest.
Excluded studies
We excluded two trials (Liu 2009, Mahony 2004). The reason
for exclusion was that trials did not evaluate interventions to pre-
vent postpartum constipation. See the Characteristics of excluded
studies table.
Risk of bias in included studies
We presented judgements regarding the risk of bias in each of the
included trials in theCharacteristics of included studies. Summary
tables of risk of bias in all included trials are also displayed in Figure
2 and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Allocation refers to both the generation of the random allocation
sequence and concealment of assignment to prevent selection bias.
Generation of allocation sequence
Allocation sequence generation method was assessed in each of
the included trials and judged as either ’Low risk’, ’High risk’
or ’Unclear’. Eogan 2007 used computer-generated numbers in
ratio of 1:1 for generating the allocation sequence, and thus was
judged to have low risk of selection bias; two trials (Diamond
1968; Shelton 1980) provided insufficient information to enable
us to judge whether there was a low or high risk of selection bias, we
therefore judged them as having unclear risk of selection bias. The
remaining two trials (Mundow 1975; Zuspan 1960) were quasi-
randomised trials, where the method used to generate allocation
sequence was not indicated. Therefore both trials were considered
as having high risk of selection bias.
Allocation concealment
Four trials (Diamond 1968; Eogan 2007; Shelton 1980 and
Zuspan 1960) were judged as having unclear risk of bias since
none of themprovided sufficient information to enable us to judge
whether the trials were of either low or high risk of selection bias.
Diamond 1968 used sealed and identical envelopes but the authors
did not report whether they were opaque and sequentially num-
bered. Eogan 2007 employed the sealed opaque envelope tech-
nique where all the tablets (active and placebo) used were identical
in number and appearance but sequential number arrangement
of the envelopes was not explicitly stated. We emailed the corre-
sponding author of Eogan 2007 requesting further information
on the method of allocation concealment but no response was
received. For Shelton 1980, the tablets (active and placebo) were
identical in all respects and women only received drugs from a
numbered bottle allocated to them. Zuspan 1960 reported that
indistinguishable capsules were given to the women but there was
no further explicit information on assignment. The fifth trial,
Mundow 1975 reported that yellow identical capsules were taken
from a numbered bottle that was assigned to each woman. The
code was held by the laboratory and was only sent to the investiga-
tors at the end of the trial. Therefore this trial was judged as having
low risk of bias for this domain. Contact details of corresponding
authors were not provided for the other trials (Diamond 1968,
Shelton 1980; Zuspan 1960).
Blinding
All included trials had unclear risk of performance bias (Diamond
1968, Eogan 2007, Mundow 1975;Shelton 1980; Zuspan 1960)
because it was unclear whether or not the participants and person-
nel were adequately blinded to the assignment. There was a lack of
sufficient and explicit information on the methods used for blind-
ing. Diamond 1968 reported that participants and investigators
were not aware of the content of the identical drugs and envelopes,
but did not provide information on identical colour, shape and
size of drug to enable explicit judgement. Eogan 2007 did not
supply any information on blinding of participants, personnel and
the investigators and it was judged as unclear risk of bias for both
performance and detection bias. Shelton 1980 reported that the
trial was “double-blind” but did not explicitly explain what steps
were followed to ensure adequate blinding of the participants and
personnel, it was therefore judged as unclear of performance bias.
Zuspan 1960 stated that the trial was “double blind” but failed
to report on whether capsules were identical in appearance, shape
and size, and no information was provided on blinding of inves-
tigators and the personnel to the assignment, thus it was judged
as unclear of performance and detection bias. Mundow 1975 re-
ported that the active and placebo tablets were indistinguishable
to participants and observers, the code was only sent to the inves-
tigator at the end of the study but did not provide information
on whether the people administering the intervention were also
prevented from identifying the interventions; hence it was judged
as having low risk of detection bias but unclear risk of perfor-
mance bias. Diamond 1968 reported that “ the knowledge of the
random code number and type of drug was not revealed till the
completion of the study”; it was therefore judged as having low
risk of detection bias. Shelton 1980 stated that “Statistical analyst
had no knowledge of which participants received active treatment
or placebo” and that the code was only broken at the final stage
of analysis and it was therefore also judged as having low risk of
detection bias.
Incomplete outcome data
In Diamond 1968, all participants in the trial were adequately
reported on and they were included in the final analysis and there-
fore the trial was considered as having low risk of attrition bias.
Two trials (Eogan 2007; Shelton 1980) were assessed as having
high risk of attrition bias. Eogan 2007 reported that all partici-
pants attended the first follow-up at 10 days postpartum, but 26
participants did not turn up for assessment at three months fol-
lowing delivery, despite the repeated reminder sent to them. Of
these, 24 gave a personal reason and two could not be traced and
were therefore excluded from the final analysis. The attrition rate
was more than 15% in both groups and the study was considered
as having high risk of attrition bias. Forty of the participants in
Shelton 1980 were excluded from the analysis because the result
showed a small difference and the number was small (according
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to trial authors); the trial was therefore considered as having high
risk of attrition bias. Two trials (Mundow 1975; Zuspan 1960)
were judged as having unclear risk of attrition bias. Mundow 1975
did not give an explicit report of the number of participants in
each trial group and there was no flow diagram to illustrate the
flow of participants. Zuspan 1960 also did not provide adequate
information on the flow of participants in the trial.
Selective reporting
All five included trials (Diamond 1968; Eogan 2007; Mundow
1975; Shelton 1980; Zuspan 1960) appeared to be free of selective
outcome reporting. The protocols were not available but all the
pre-specified outcomes stated in the methods section of each trial
were adequately reported. All trials were therefore judged as having
low risk of selective reporting bias.
Other potential sources of bias
Diamond 1968 and Zuspan 1960 were supported by drug compa-
nies (Wyeth Laboratories and Purdue Fredrick Co, respectively).
There was no declaration of interest and the trial authors did not
specify whether the companies influenced the results or not. Con-
sequently Diamond 1968; and Zuspan 1960 were judged as hav-
ing unclear risk of other bias. Mundow 1975 was also judged as
having an unclear risk of bias because the trial report did not con-
tain information on conflicts of interest, funding sources, how the
sample size was determined or whether ethical approval was ob-
tained.
Shelton 1980 was judged to be at high risk of other bias. The
authors reported that the drugs used in the trial and statistical
evaluation were provided by Reckitt & Colman, but there was
no information on declaration of interest to ascertain whether the
company might have influenced the trial results or not. There was
also no information relating to ethical approval.
Eogan 2007 appeared to be free of other bias.
Effects of interventions
The five included trials (Diamond 1968; Eogan 2007; Mundow
1975; Shelton 1980; Zuspan 1960) examined two different com-
parisons given below.
Laxative versus placebo - Comparison 1
Four included trials (Diamond 1968; Mundow 1975; Shelton
1980; Zuspan 1960) examined the effectiveness and safety of a
laxative versus a placebo control. The laxatives studied by the
four trials were as follows: studied Bisoxatin acetate (Diamond
1968); active senna (Shelton 1980); Dorbanex (Mundow 1975);
and Dioctyl-sodium succinate plus senna (Zuspan 1960).
Primary outcomes
Pain or straining on defecation
None of the four trials evaluating this comparison reported on
pain or straining during defecation.
Incidence of postpartum constipation as per self-report and
other diagnostic criteria
None of the four trials evaluating this comparison reported on the
incidence of postpartum constipation.
Changes in quality of life as measured in included studies
(using e.g. maternal postpartum quality of life (MAPP-QOL)
questionnaire)
None of the four trials evaluating this comparison reported on
changes in quality of life.
Time to first bowel movement (days) (outcome not pre-
specified in our protocol)
Four trials reported on this outcome (Diamond 1968; Mundow
1975; Shelton 1980; Zuspan 1960). Three trials (Diamond 1968;
Mundow 1975; Shelton 1980) reported on the number of women
having their first bowel movement on the day of delivery, day one,
day two, day three, and day four. Zuspan 1960 reported the mean
days to first bowel movement. We analysed data accordingly.
Number of women having their first bowel movement in less
than 24 hours
Results from one trial (Shelton 1980) found thatmore women had
their first bowel movement in less than 24 hours in the laxative
group compared to the placebo group (142/224 (63%) versus 54/
247(21.9%), risk ratio (RR) 2.90, 95% confidence interval (CI)
2.24 to 3.75, 471 women, one trial) (Analysis 1.1).
Number of women having their first bowel movement on day
one
Results from random-effects meta-analysis of three trials (
Diamond 1968; Mundow 1975; Shelton 1980) showed substan-
tial unexplained heterogeneity between trials (Tau² = 0.14; Chi²
= 5.45, P = 0.07; I² = 63%). We therefore did not carry out meta-
analysis; in the data and analysis we report subtotals only and set
out the results of individual trials. Diamond 1968 found thatmore
women in the laxative group had their first bowel movement on
day one when compared to women in the placebo group (23/54
(42.6%) versus 11/52 (21.2%), RR 2.01, 95% CI 1.09 to 3.70,
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106 women). Results from Mundow 1975 (7/100 (7%) versus
9/100 (9%), RR 0.78, 95% CI 0.30 to 2.01, 200 women); and
Shelton 1980 (69/224 (31%) versus 81/247 (4.0%), RR 0.94,
95% CI 0.72 to 1.22, 471 women) showed no difference between
laxative and placebo groups (Analysis 1.2).
Number of women having their first bowel movement on day
two
Random-effects meta-analysis of three trials (Diamond 1968;
Mundow 1975; Shelton 1980) showed substantial unexplained
heterogeneity between trials (Tau² = 2.27; Chi² = 45.00, P <
0.00001, I² = 98%). We therefore report on the results of in-
dividual trials. Diamond 1968 and Mundow 1975 both found
that more women in the laxative group had their first bowel
movement on day two compared to the placebo group (26/54
(48.1%) versus 9/52 (17.3%), RR 2.78, 95% CI 1.44 to 5.36,
106 women, (Diamond 1968), and 49/100 (49%) versus 12/100
(12%), RR 4.08, 95% CI 2.32 to 7.20, 200 women, (Mundow
1975) ).Shelton 1980 found that fewer women in the laxative
group compared to the placebo group had their first bowel move-
ment on day two (9/224 (4.0%) versus 44/247(17.8%), RR 0.23,
95% CI 0.11 to 0.45, 471 women) (Analysis 1.3).
Number of women having their first bowel movement on day
three
Random-effects meta-analysis of two trials (Mundow 1975;
Shelton 1980) showed substantial unexplained heterogeneity be-
tween trials (Tau² = 3.89; Chi² = 4.65, P = 0.03; I² = 78%).
We therefore report on the results of individual trials. One trial
(Shelton 1980) found that fewer women had their first bowel
movement on day three in the laxative group compared to the
placebo group (0/224 (0%) versus 10/247 (4.0%), RR 0.05, 95%
CI 0.00 to 0.89, 471 women) whereas the other trial (Mundow
1975) found no clear difference between the two groups (30/100
(30%) versus 33/100 (33%), RR 0.91, 95% CI 0.60 to 1.37, 200
women) (Analysis 1.4).
Number of women having their first bowel movement on day
four
Random-effects meta-analysis of two trials (Mundow 1975;
Shelton 1980) found a clear difference where, on average, signif-
icantly fewer women in the laxative group had their first bowel
movements on day four compared to the placebo group (RR 0.36,
95% CI 0.21 to 0.61, 671 women) and there was no substantial
statistical heterogeneity detected between the trials (Tau² = 0.00,
Chi² = 0.21, P = 0.65, I² = 0%) (Analysis 1.5).
Number of days to first bowel movement
Zuspan 1960 reported the mean number of days before the first
bowel movement occurred as 2.48 days versus 2.55 days for the
laxative versus placebo groups. However, since there were no stan-
dard deviations and P values reported we are unable to analyse
these data further.
Secondary outcomes
Stool consistency using Bristol stool form scale
Therewere no trials reporting on stool consistency using theBristol
stool form scale. However, Diamond 1968 reported the number
of women having loose or watery stools and noted that there were
more women with this outcome in the laxative group compared to
the placebo group (28/54 (51.9%) versus 1/52 (1.9%), RR 26.96,
95% CI 3.81 to 191.03, 106 women, one trial, Analysis 1.6). The
wide CI is due to the fact there was only event in the placebo
group.
Use of alternative products, laxative agents, enemas
Zuspan 1960 reported the number of postpartum enemas given
and there was no difference between the laxative and placebo
groups (20/123 (16.3%) versus 31/121 (25.6%), RR 0.63, 95%
CI 0.38 to 1.05, 244 women, one trial, Analysis 1.7).
Mundow 1975 reported the number of women receiving suppos-
itories or enemas and there were fewer women receiving these in
the laxative group compared to the placebo group (7/100 (7%)
versus 24/100 (24%), RR 0.29, 95% CI 0.13 to 0.65, 200 partic-
ipants, one trial, Analysis 1.8).
Relief of abdominal pain/discomfort
None of the four trials evaluating this comparison reported on
relief of abdominal pain/discomfort.
Stool frequency
Diamond 1968 reported the number of women having more than
two bowel movements per day. There were more women having
more than two bowel movements per day in the laxative group
compared to the placebo group (13/54 (24.1%) versus 0/52 (0%),
RR 26.02, 95%CI 1.59 to 426.73, 106 women, one trial, Analysis
1.9). The wide confidence interval is due to the fact that there
were zero events in the placebo group.
Mundow 1975 reported the number of days (from zero tofive days)
that women recorded bowled movements (Analysis 1.10). Fewer
women had no bowel movement for five days in the laxative group
compared to women in the placebo group (0/100 (0%) versus 9/
100 (9%), RR 0.05, 95% CI 0.00 to 0.89, 200 women).There
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were no differences between the laxative and placebo groups in
the number of women having bowel movements on one, three
and five days. However, there were fewer women having bowel
movements on two days in the laxative compared to the placebo
group (25/100 (25%) versus 42/100 (42%), RR 0.60, 95% CI
0.39 to 0.90, 200 women, one trial,). Conversely, more women
had bowel movements on four days in the laxative compared to
the placebo group (27/100 (27%) versus 10/100(10%), RR 2.70,
95% CI 1.38 to 5.28, 200 women, one trial).
Adverse effects caused by the intervention
Shelton 1980 and Mundow 1975 reported on the number of
womenhaving abdominal cramps but their results were not pooled
in a meta-analysis due to substantial statistical heterogeneity (Tau²
= 3.32; Chi² = 5.63, P = 0.02; I² = 82%, Analysis 1.11). While
Shelton 1980 reported that more women were having abdomi-
nal cramps in the laxative group compared to the placebo group
(23/224 (10.3%) versus 6/247 (2.4%), RR 4.23, 95% CI 1.75
to 10.19, 471 women, one trial), there were no clear difference
between the laxative and placebo groups in Mundow 1975 (RR
0.25, 95% CI 0.03 to 2.20, 200 women, one trial).
Any adverse effects of the intervention on the baby
Shelton 1980 reported on adverse effects of the intervention on
the baby and there were no clear differences in the incidence of
loose stools (RR 0.62, 95% CI 0.16 to 2.41, 281 women, one
trial) or diarrhoea (RR 2.46, 95% CI 0.23 to 26.82, 281 women,
one trial) between the two groups (Analysis 1.12).
Laxative alone versus laxative plus a bulking agent -
Comparison 2
One trial (Eogan 2007) compared a laxative (Lactulose) alone
versus the same laxative plus a bulking agent (Lactulose plus a
sachet of Ispaghula husk) in women who had sustained sphincter
injuries during vaginal delivery and had subsequently undergone
surgical repair of the tear.
Primary outcomes
Pain or straining on defecation
Eogan 2007 reported on the level of pain or discomfort with the
first postpartum bowel movement using a Likert scale (1 = no pain
to 5 = excruciating pain) during the first 10 days postpartum. The
median (range) pain score for both study groups was one (one
to five) and there were no differences between the two groups (P
= 0.11, as reported by trial authors). We were unable to further
analyse these data since the data were only reported in terms of
medians (range).
Incidence of postpartum constipation as per self report and
other diagnostic criteria
Eogan 2007 reported that there was no difference in incidence of
postpartum constipation (data not reported).
Changes in quality of life as measured in included studies
(using e.g. maternal postpartum quality of life (MAPP-QOL)
questionnaire)
Change in quality of life was not reported by the trial evaluating
this comparison.
Time to first bowel movement (days)
Eogan 2007 reported that the first postpartum bowel motion oc-
curred at a median (range) of three (one to six) days and three
(one to five) days in the two groups and there was no difference
between the two groups (P = 0.34).
Secondary outcomes
Stool consistency using Bristol stool form scale
Stool consistency was not reported by the trial assessing this com-
parison.
Use of alternative products, laxative agents, enemas
Use of alternative products, laxative agents, enemas was not re-
ported by the trial assessing this comparison.
Relief of abdominal pain/discomfort
Relief of abdominal pain/discomfort was not reported by the trial
evaluating this comparison.
Stool frequency
Stool frequency was not reported by the trial assessing this com-
parison.
Adverse effects caused by the intervention
Eogan 2007 reported incontinence using a bowel function ques-
tionnaire with score from 0 to 20 (0 = incomplete continence up
to 20 = complete incontinence). Scores were assigned according to
participants’ symptoms including faecal urgency or incontinence
as well as flatus incontinence on day three, day 10 and after three
months postpartum. The incontinence score on day three in the
laxative plus bulking agent group was significantly higher than in
the laxative alone group (median (range): one (0 to 10) versus 0
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(0 to 12) respectively, P = 0.02 as reported by trial authors). How-
ever, there was no difference in the incontinence scores between
the two groups at three months postpartum (median (range): 0 (0
to six) versus 0 (0 to 10) respectively, P = 0.57 as reported by trial
authors). No further analysis was possible since results were only
reported as medians (range).
The trial also reported the number of participants having any
episode of faecal incontinence during first 10 postpartum days.
There was no clear difference in the number of women having any
episode of faecal incontinence during the first 10 postpartum days
between the two groups (14/77 (18.2%) versus 23/70 (32.9%),
RR 0.55, 95% CI 0.31 to 0.99, 147 women, one trial, Analysis
2.1).
Any adverse effects of the intervention on the baby
The trial evaluating this comparison did not report on adverse
effects of the intervention on the baby.
D I S C U S S I O N
Summary of main results
The objective of this review was to assess the effectiveness and sa-
fety of different interventions for preventing postpartum consti-
pation. We conducted a comprehensive electronic search of po-
tential trials, without language restrictions. We included five trials
(involving a total of 1208 postpartum women) in this review.
All Included trials dealt with the prevention of postpartum consti-
pation by administering laxatives within the first day of the post-
partum period. The quality of included trials was poor, with un-
clear risk of bias for most domains across trials. Although the re-
sults of some of the outcomes showed clear differences between
groups within single trials, the trials varied in sample size, duration
of study, interventions and reported outcomes, which limited the
number of meta-analyses that could be done.
Four trials (Diamond 1968; Mundow 1975; Shelton 1980;
Zuspan 1960) compared a laxative and a placebo.None of the trials
reported on the primary outcomes of the review: pain or straining
on defecation; incidence of postpartum constipation; or changes
in quality of life. For the outcome ’number of days to first bowel
movement’, trials reported the number of women having their first
bowel movement on day one to day four postpartum. Random-ef-
fects meta-analysis, done per day postpartum, showed substantial
unexplained heterogeneity for days one to three and results were
therefore reported per trial. No heterogeneity was present in the
meta-analysis for day four, and a pooled result was reported. On
day four, a random effects meta-analysis of two trials showed that
on average, more women in the placebo group were having their
first bowel movement compared to the laxative group.
This review’s secondary outcomes were poorly reported in the
included trials. Diamond 1968 reported on stool frequency as an
adverse effect of the intervention (Bisoxatin) and the results show
a higher stool frequency in the laxative group compared to the
placebo group. The same trial reported on stool consistency, with
more women in the laxative group compared to the placebo group
having experienced loose or watery stools. According to Shelton
1980, loose stools or diarrhoea in both mother and babies could
not be attributed to administration of senna given to themother in
the early postpartumperiod, however therewere significantlymore
women in the laxative group with abdominal cramps ranging from
mild to severe. Both trials did not report on the use of additional
products or changes in quality of life.
The fifth trial (Eogan 2007) compared a laxative (oral Lactulose)
versus the same laxative plus a bulking agent (Ispaghula husk) in
women undergoing surgical repair of a third degree perineal tear.
The trial found no clear difference in pain scores between the two
groups in relation to first postpartumbowelmotion.However, fear
of pain caused by the repaired perineal tear or episiotomy could
cause a postpartum woman to refrain from emptying her bowel
when she has the urge to defecate, which in turn could lead to
constipation. Considering this, it would be difficult to ascertain
whether the pain was due to the repaired perineal tear or due to
postpartum constipation. The trialist reported no clear difference
between groups regarding time to first bowel movement (data pro-
vided as median and range, not analysed further in this review).
The trial did not provide data in relation to the incidence of post-
partum constipation (but reported no clear difference between
groups). Change in quality of life was not reported. Adverse ef-
fects were the only secondary outcomes reported. The trial found
a higher risk of faecal incontinence at 10 days postpartum in the
laxative plus bulking agent group, but the trialist reported that
there was no difference after threemonths (and loss to follow-up at
three months was high for this group (Lactulose = 16%, Lactulose
plus Ispaghua husk = 20%).
Overall completeness and applicability of
evidence
The five trials were conducted in three different countries (United
States of America, Ireland and South Africa), all in tertiary hospi-
tals. Three of the trials (Diamond 1968; Mundow 1975; Shelton
1980) examined the time to first bowel movement (days) as one
of the their outcomes. All included trials assessed pharmaceutical
interventions in preventing postpartum constipation.
None of the trials assessed other interventions such as dietary ad-
vice and modification, promotion of healthy physical activities
and correct positioning for defecation, which also have a very im-
portant place in promoting bowel movement during the postpar-
tum period. Consideration also needs to be given to other factors
that might influence postpartum bowel movement, such as the
administration of enemas before labour, the ability of women to
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eat during active labour, and irregular and altered eating habits
during the first few days after delivery. None of these factors were
reported on in the included trials. In addition, included trials only
assessed bowel movements during the first five days after deliv-
ery. Constipation can become a problem at a later stage of the
postpartum period, up to six months postpartum (Van Brummen
2006). Factors such as limited physical exercise, irregular and al-
tered dietary pattern, insufficient intake of fluids and emotional
concerns of being a new mother may have a negative influence on
bowel movements during this period (National Institute of Health
2013).
One trial (Eogan 2007), evaluated two different interventions
amongst women who had undergone surgical repair of a third de-
gree perineal tear. This is a very specific group of trial participants
and the results can therefore not be extrapolated to the general
postpartum woman. The pain experienced with the first bowel
movement was most likely attributed to pain due to the perineal
tear and surgery and not necessarily due to constipation. Fear of
pain can also play a role in this group of women, which might lead
to constipation.
Only a few adverse effects were reported in the included trials and
there is thus insufficient evidence to make general conclusions on
safety and effectiveness of these interventions.
Quality of the evidence
All the five trials included in this review lacked methodological
rigour. Two trials are quasi-randomised controlled trialswith a high
risk of selection bias. Only one trial (Eogan 2007) reported an ad-
equate method for sequence generation. Allocation concealment
was unclear in four trials (Diamond 1968; Eogan 2007; Shelton
1980; Zuspan 1960), while Mundow 1975 adequately reported
on allocation concealment. Blinding was poorly reported in all
included trials. All included trials were judged as having unclear
risk of performance bias due to insufficient information.Diamond
1968; Mundow 1975 and Shelton 1980 had low risk of detection
bias while Eogan 2007 and Zuspan 1960 were judged as having
unclear risk of detection bias. One trial was judged as having low
risk of attrition bias (Diamond 1968); Eogan 2007 and Shelton
1980 had a high risk of attrition bias due to incomplete outcome
data, and Mundow 1975 and Zuspan 1960 were judged as hav-
ing unclear risk of attrition bias due to insufficient information
provided. The drugs used in three of the trials (Diamond 1968;
Shelton 1980; Zuspan 1960) were supplied by a drug company
and we cannot rule out the possibility that the company may have
influenced the trial results since there was no declaration of in-
terest. Shelton 1980 had high risk of other bias due to statistical
analysis provided by the same drug company that supplied the
drugs for the trial, while Eogan 2007 had low risk of other bias.
All included trials were free of selective outcome reporting bias.
Potential biases in the review process
Weattempted tominimise potential bias in this review in anumber
of ways. A comprehensive trial search was conducted to include
published and unpublished trials in all languages. At least two
review authors independently scrutinised and selected trials for
inclusion in the review using eligibility criteria, assessed risk of
bias, and extracted data. We were unable to examine reporting
biases using funnel plots, as we had less than 10 included trials
in a meta-analysis.The primary outcome ’number of days to first
bowelmovement’ was supposed to be analysed using time-to-event
analysis methods, but this could not be done due to insufficient
individual patient data on censoring. The separate analyses per
day do not take account of the fact that the denominator was
decreasing as the number of days after delivery increased due to
the fact that once a woman experienced the event, they could not
experience the event again thereafter.
Agreements and disagreements with other
studies or reviews
There is noother systematic reviewon interventions for preventing
postpartum constipation. Dietary fibre in the form of e.g. wheat
and brans offers relief for constipation in non-pregnant mothers
and raise no serious concerns about side effects tomother and baby.
Othermeasures such as behavioural and educational interventions,
increased exercise and positioning during bowel movement were
not discussed in the included trials. Symptomatic rectal haemor-
rhoids also play a significant role in postpartum constipation and
dietary fibre seems to offer effective treatment in relieving haem-
orrhoids which may contribute to constipation (Alonso-Coello
2005).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to make general conclusions about
the effectiveness and safety of laxatives during the immediate post-
partum period (up to five days postpartum). Trials did not follow
participants up through the entire postpartum period and we did
not find any evidence on the effectiveness and safety regarding
the use of laxatives during the entire postpartum period up to six
months. The evidence from one small trial suggests that the use
of stool-bulking agent in addition to a laxative to initiate bowel
movement in women who sustained anal sphincter injury at vagi-
nal delivery does not improve postnatal pain or straining on defe-
cation.
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Implications for research
There are few trials on interventions for preventing postpartum
constipation reporting on the following important outcomes: pain
or straining on defecation; incidence of postpartum constipation,
quality of life, time to first bowel movement after delivery, and
adverse effects caused by the intervention such as: nausea or vom-
iting, pain and flatus. No trials evaluating non-pharmacological
interventions (such as acupuncture, educational or behavioural
interventions and positioning during bowel movement) are cur-
rently available. Further large, rigorous randomised controlled tri-
als are needed to address the safety and effectiveness of laxatives
for preventing constipation during the entire postpartum period.
Trials assessing educational and behavioural interventions aiming
to promote a healthy diet and physical activity in preventing post-
partum constipation are also needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Diamond 1968
Methods Study design: randomised controlled trial.
Trial duration: 12 weeks (April 11, 1966 to July 13, 1966).
Trial location: University of Minnesota Hospitals, Minneapolis, USA
Participants Number of participants: 106 postpartum women aged 15-41 years
Intervention group: 54 women (29 primiparous and 25 multiparous)
Control group: 52 women (26 primiparous and 26 multiparous).
Interventions Intervention: Bisoxatin acetate (3 tablets); 1 tablet was given orally 1st day postpartum
and if no bowel action occur that 1st day, the dose was increased to 2 tablets by the 2nd
day. If no bowel activity occur by the 3rd day other form of laxative was used
Control: lactose placebo (3 tablets).
Outcomes Primary outcomes
1. Number of participants having their first bowel movement by day 1, day 2, and day 3
2. Number of stools per day.
3. Side effects: diarrhoea, loose or watery stool.
Notes Ethics approval: not stated.
Funding: the study was supported by the Wyeth Laboratories, Philadelphia, Pennsylva-
nia, USA
Correspondence with authors: no email address available. We would have requested
details regarding risk of bias, for instance whether random number tables or a computer
were used in random sequence generation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote “Each patient was assigned a num-
ber according to a random code”. It is un-
clear how the random sequence was gener-
ated
Allocation concealment (selection bias) Unclear risk Quote “Identical envelopes and drugs were
used”. It was not clear whether adequate
precaution were taken to conceal the as-
signment from the participants and inves-
tigators
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote “The patients and investigators were
not aware of the content of the identical
drugs and envelopes”. Insufficient informa-
tion on identical colour, shape and size of
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Diamond 1968 (Continued)
drug to enable explicit judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote “The knowledge of the randomcode
number and type of drug was not revealed
till the completion of the study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. All women en-
rolled were included in the final analysis
Selective reporting (reporting bias) Low risk No published protocol available, but all
outcomes that were pre-specified in the
methods session were addressed
Other bias Unclear risk The study was supported by Wyeth Labo-
ratories but the trial authors do not specify
whether the drug company influenced the
results
Eogan 2007
Methods Study design: randomised controlled trial.
Trial duration: 12 months (May, 2003 to April, 2004).
Trial location: National Maternity Hospital, Holles St Dublin, Ireland
Participants Participants: 147 postpartum women with sphincter injury at vaginal delivery, under-
going primary repair of a recognised anal sphincter tear
Intervention group: 70 postpartum women.
Control group: 77 postpartum women.
Exclusion criteria: history of colorectal disease, inflammatory bowel disease, diabetes
mellitus or colorectal malignancy
Interventions Intervention: oral lactulose 10 mL thrice daily for the first 3 postpartum days followed
by sufficient lactulose to maintain a soft stool for 10 days plus 1 sachet of Ispaghula husk
for 10 days
Control: oral lactulose 10 mL thrice daily for the first 3 postpartum days followed by
sufficient lactulose to maintain a soft stool for 10 days
All patients were given routine antibiotic (co-amoxyclavulanic acid), while erythromycin
and metronidazole were used in those with penicillin allergy
All participants were provided with a diary card to keep record of their bowel habits and
motions for 10 days
Opiate was avoided in both groups.
Outcomes Primary outcomes
1. Discomfort with 1st postpartum bowel motion (using pain scale from 1 - no pains to
5 - excruciating pains)
2. Incidence of postnatal constipation and incontinence.
Secondary outcomes
1. Time until first bowel motion.
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Eogan 2007 (Continued)
2. Duration of postnatal stay.
3. Symptomatic and functional outcomes 3 months postpartum.
All participants were provided with a diary card to keep record of their bowel habits and
motions for 10 days, opiate was avoided in both groups
Notes Funding: the study was supported by the Irish Health research board
Correspondence: email was sent to the author (colm.oherlihy@ucd.ie) requesting for
further information on method used to ensure adequate concealment of the assignment
and blinding processes, but there was no response
Declaration of interest: no comment provided.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out using com-
puter-generated allocations
Allocation concealment (selection bias) Unclear risk ”Sealed opaque envelopes was used to con-
cealed allocation identity”. It was not spec-
ified whether the envelopes were sequen-
tially numbered to prevent selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk There was no explicit information on
blinding of the participants, personnel and
investigators to the assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge whether
the assessors were blinded to the assign-
ment or not
Incomplete outcome data (attrition bias)
All outcomes
High risk All participants attended the first 10 days
follow-up, 26 did not attend postpartum
review at 3 months despite 2 repeated ap-
pointments sent, 24 of whom gave a per-
sonal reason and 2 could not be traced
Attrition rate in intervention group (LG) =
16%.
Attrition rate in control group (FG) = 20%.
Selective reporting (reporting bias) Low risk All outcomes that were pre-specified in the
methods were addressed
Other bias Low risk The study appears to be free of other
sources of bias.
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Mundow 1975
Methods Study design: quasi-randomised trial.
Trial Duration: 6 weeks (May 5th,1974 to June11th, 1974).
Trial location: St James’ Hospital Dublin. Ireland.
Participants 200 normal postpartum women.
Intervention group: 100 primiparous and multiparous women.
Control group: 100 primiparous and multiparous women.
Interventions Intervention:Danthron/Poloxalkol (Dorbanex). Each patient was given2 yellow capsules
at 18:00 hour every evening starting from the 3rd day of delivery for the next 3 days (6
capsules). The capsules were taken from numbered bottles
Control: ’Placebo’ - author did not give name of placebo; It was said that an identical
code was used for both the placebo and experimental intervention
Outcomes Outcomes
1. Number of days to first bowel movement.
2. Visible haemorrhoids.
3. Abdominal pain.
Secondary outcomes
4. Diarrhoea.
5. Nausea.
6. Urine discolorations.
Notes There was no information on number of participants in each arm of intervention. Ethical
approval not stated and declaration of interest not provided. The funding organisation
was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote ”Consecutive patients were enrolled
into study, Randomization component not
explicitly stated”
Allocation concealment (selection bias) Low risk Quote ‘’The yellow identical capsules were
taken from a numbered bottle, each of
which contained 6 capsules. There were
200 bottles and one was assign to each par-
ticipant. The code was held by the labora-
tories and was only sent to the investigators
at the end of the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote “The placebo and the active cap-
sules were indistinguishable to the partic-
ipant”. No information on the personnel
and method used in blinding the both par-
ticipant and the personnel
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Mundow 1975 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote “The code which identify the active
from the placebo was held at Riker Labora-
tories at Loughborough and was sent to the
investigator only at the end of the study, the
active and placebo were indistinguishable”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of participants in each group
was not stated explicitly and there was no
flow diagram to illustrate this
Selective reporting (reporting bias) Low risk Study protocol was not available, but all
outcomes specified in the method section
were addressed
Other bias Unclear risk There was no information on conflicts of
interest, how sample size was determined
and no comment was made on ethical ap-
proval. The funding organisation was not
reported
Shelton 1980
Methods Study design: randomised controlled trial.
Trial setting: multicentre.
Trial location: Department of Obstetrics and Gynaecology,University of Cape Town,
Groote Schuur Hospital and Peninsula Maternity Hospitals, Cape Town South Africa
Participants Participants: 511 normal postpartum women with vaginal delivery
White postpartum women: 267 (from GrooteSchuur Hospital).
Coloured postpartum women: 204 (Peninsula Maternity Hospital)
Black postpartum women: 40.
Exclusion criteria: women delivered by caesarean section or complicated by 3rd degree
perineal tear
Interventions Intervention: active senna tablets, 2 tablets were given in themorning and 2 tablets in the
evening immediately after delivery, and 2 tablets twice daily until bowel action occurred
or end of regimen (16 tablets used up)
Control: placebo (powdered corn flakes and dried grass).
Outcomes Primary outcomes
1. Initial spontaneous bowel movement within the first 24 hours of delivery
2. Initial spontaneous bowel movement within 48 hours of delivery
3. First bowel movement on the third day of delivery.
4 .Time of dosage.
5.Time and nature of bowel action.
Infant side effects
1. Loose stools or diarrhoea.
2. Number, colour and nature of stools for duration of trial
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Shelton 1980 (Continued)
3. Proportion of babies with normal stools.
4. Mode of feeding.
Secondary outcomes
1. Enema during labour and state of perineum following delivery
2. Maternal side effects: e.g. abdominal colic pains.
3. Mode of delivery.
Notes Sponsor: the drugswere supplied byReckitt&Colman and statistical evaluationprovided
by them
Ethics approval: not stated.
Decaration of interest: not disclosed.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Author did not provide sufficient infor-
mation on how randomisation was done.
Quote ”Trial preparation was administered
according to a strict double - blind random
selection procedure”
Allocation concealment (selection bias) Unclear risk The authors did not provide sufficient in-
formation to enable a clear judgement.
Quote ”tablets (active and placebo) were
identical in all respect and patient only re-
ceived drugs from a numbered bottle allo-
cated to her”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote “Treatment assignment was masked
from all study personnel and participants
for the duration of the study”. Information
on methods used to mask the colour, shape
and size was not supplied
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote “Statistical analyst had no knowl-
edge of which patients received active treat-
ment or placebo”. The code was only bro-
ken at the final stage of analysis
Incomplete outcome data (attrition bias)
All outcomes
High risk The result of 40 participants was not in-
cluded because the results showed minimal
differences
Selective reporting (reporting bias) Low risk All the pre-specified outcomes in the
method section were addressed adequately
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Shelton 1980 (Continued)
Other bias High risk Sponsor: the drugs used were supplied by
Reckitt & Colman and statistical evalua-
tion provided by them
Ethics approval: not stated.
Declaration of interest: not disclosed.
Zuspan 1960
Methods Study design: quasi-randomised trial.
Trial setting:Department ofObstetrics andGynaecology, UniversityHospital Cleveland,
Ohio. United States of America
Trial location: United States of America.
Participants 244 postpartum women.
Interventions Intervention: Dioctyl-sodium succinate (50 mg) + senna (225 mg); 1 capsule twice daily.
The 1st capsule was given as soon postpartum as practical. No other laxative drugs given
except enema saponis at patients’ request
Control: capsulated inert ingredients (placebo), 1 capsule twice daily. 1st dose given as
soon as postpartum is practical. No other laxative administered except enema saponis at
patients’ request
Outcomes 1. Number of days before 1st spontaneous bowel movement.
2. Number of capsule (laxative) taken before 1st spontaneous bowel movement
3. Number of postpartum enemas given.
Notes Purdue Fredrick Co. supplied the laxative (Senokap) used for the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk There was no information on random allo-
cation sequence generation method (quasi-
RCT)
Allocation concealment (selection bias) Unclear risk Insufficient information to enable us make
a clear judgement on allocation conceal-
ment
Quote: “Indistinguishable coded capsules
were given to the patients”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote “All patients received double
blinded capsule as soon as postpartum is
practical and they were intentionally not
told whether the capsule was a laxative or
not”. No report on method used blinding
the both the participants and personnel
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Zuspan 1960 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was given on knowledge
of allocation interventions been prevented
during measurement of outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information was provided on the flow
of participants.
Selective reporting (reporting bias) Low risk No published protocol available, but the
pre-specified outcomes were addressed ad-
equately
Pre-specified outcomes.
1. Number of days before 1st spontaneous
bowel movement.
2. Number of capsule (laxative) taken be-
fore 1st spontaneous bowel movement
3. Number of postpartum enemas given.
Other bias Unclear risk Ethics approval not stated.
Purdue Fredrick Co. supplied the laxative
(Senokap) used for the trial
Conflict of interest was not addressed; we
are not sure if there is a conflict of interest
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Liu 2009 Trial did not study interventions to prevent postpartum constipation
Mahony 2004 Trial did not study interventions to prevent postpartum constipation
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D A T A A N D A N A L Y S E S
Comparison 1. Laxative versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of days to first bowel
movement:less than 24 hours
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Number of days to first bowel
movement: day one
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Number of days to first bowel
movement: day two
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Number of days to first bowel
movement: day three
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5 Number of days to first bowel
movement: day four
2 671 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.21, 0.61]
6 Stool consistency - loose or
watery stools
1 106 Risk Ratio (M-H, Fixed, 95% CI) 26.96 [3.81, 191.03]
7 Number of postpartum enemas
given
1 244 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.38, 1.05]
8 Number receiving suppositories
or enemas
1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.13, 0.65]
9 Number having two or more
bowel movements per day
1 106 Risk Ratio (M-H, Fixed, 95% CI) 26.02 [1.59, 426.73]
10 Number of days a movement
occurred
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Zero days 1 200 Risk Ratio (M-H, Random, 95% CI) 0.05 [0.00, 0.89]
10.2 One day 1 200 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.45, 2.80]
10.3 Two days 1 200 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.39, 0.90]
10.4 Three days 1 200 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.88, 2.06]
10.5 Four days 1 200 Risk Ratio (M-H, Random, 95% CI) 2.7 [1.38, 5.28]
10.6 Five days 1 200 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.22, 2.89]
11 Number having abdominal
cramps
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12 Adverse effects on the baby 1 562 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.26, 2.83]
12.1 Loose stools 1 281 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.16, 2.41]
12.2 Diarrhoea 1 281 Risk Ratio (M-H, Random, 95% CI) 2.46 [0.23, 26.82]
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Comparison 2. Laxative alone versus laxative plus bulking agent
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Faecal incontinence during first
10 postpartum days
1 147 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.31, 0.99]
Analysis 1.1. Comparison 1 Laxative versus placebo, Outcome 1 Number of days to first bowel
movement:less than 24 hours.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 1 Number of days to first bowel movement:less than 24 hours
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shelton 1980 142/224 54/247 2.90 [ 2.24, 3.75 ]
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
More in placebo group More in laxative group
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Analysis 1.2. Comparison 1 Laxative versus placebo, Outcome 2 Number of days to first bowel movement:
day one.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 2 Number of days to first bowel movement: day one
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Diamond 1968 23/54 11/52 2.01 [ 1.09, 3.70 ]
Mundow 1975 7/100 9/100 0.78 [ 0.30, 2.01 ]
Shelton 1980 69/224 81/247 0.94 [ 0.72, 1.22 ]
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
More in placebo group More in laxative group
Analysis 1.3. Comparison 1 Laxative versus placebo, Outcome 3 Number of days to first bowel movement:
day two.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 3 Number of days to first bowel movement: day two
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Diamond 1968 26/54 9/52 2.78 [ 1.44, 5.36 ]
Mundow 1975 49/100 12/100 4.08 [ 2.32, 7.20 ]
Shelton 1980 9/224 44/247 0.23 [ 0.11, 0.45 ]
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
More in placebo group More in laxative group
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Analysis 1.4. Comparison 1 Laxative versus placebo, Outcome 4 Number of days to first bowel movement:
day three.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 4 Number of days to first bowel movement: day three
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mundow 1975 30/100 33/100 0.91 [ 0.60, 1.37 ]
Shelton 1980 0/224 10/247 0.05 [ 0.00, 0.89 ]
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
More in placebo group More in laxative group
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Analysis 1.5. Comparison 1 Laxative versus placebo, Outcome 5 Number of days to first bowel movement:
day four.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 5 Number of days to first bowel movement: day four
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mundow 1975 14/100 38/100 93.9 % 0.37 [ 0.21, 0.64 ]
Shelton 1980 1/224 5/247 6.1 % 0.22 [ 0.03, 1.87 ]
Total (95% CI) 324 347 100.0 % 0.36 [ 0.21, 0.61 ]
Total events: 15 (Laxative), 43 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.81 (P = 0.00014)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
More in placebo group More in laxative group
Analysis 1.6. Comparison 1 Laxative versus placebo, Outcome 6 Stool consistency - loose or watery stools.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 6 Stool consistency - loose or watery stools
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Diamond 1968 28/54 1/52 100.0 % 26.96 [ 3.81, 191.03 ]
Total (95% CI) 54 52 100.0 % 26.96 [ 3.81, 191.03 ]
Total events: 28 (Laxative), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.30 (P = 0.00097)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
More in placebo group More in laxative group
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Analysis 1.7. Comparison 1 Laxative versus placebo, Outcome 7 Number of postpartum enemas given.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 7 Number of postpartum enemas given
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zuspan 1960 20/123 31/121 100.0 % 0.63 [ 0.38, 1.05 ]
Total (95% CI) 123 121 100.0 % 0.63 [ 0.38, 1.05 ]
Total events: 20 (Laxative), 31 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laxative Favours placebo
Analysis 1.8. Comparison 1 Laxative versus placebo, Outcome 8 Number receiving suppositories or
enemas.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 8 Number receiving suppositories or enemas
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mundow 1975 7/100 24/100 100.0 % 0.29 [ 0.13, 0.65 ]
Total (95% CI) 100 100 100.0 % 0.29 [ 0.13, 0.65 ]
Total events: 7 (Laxative), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.04 (P = 0.0024)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laxative Favours placebo
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Analysis 1.9. Comparison 1 Laxative versus placebo, Outcome 9 Number having two or more bowel
movements per day.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 9 Number having two or more bowel movements per day
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Diamond 1968 13/54 0/52 100.0 % 26.02 [ 1.59, 426.73 ]
Total (95% CI) 54 52 100.0 % 26.02 [ 1.59, 426.73 ]
Total events: 13 (Laxative), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.022)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
More in placebo group More in laxative group
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Analysis 1.10. Comparison 1 Laxative versus placebo, Outcome 10 Number of days a movement occurred.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 10 Number of days a movement occurred
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Zero days
Mundow 1975 0/100 9/100 100.0 % 0.05 [ 0.00, 0.89 ]
Subtotal (95% CI) 100 100 100.0 % 0.05 [ 0.00, 0.89 ]
Total events: 0 (Laxative), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
2 One day
Mundow 1975 9/100 8/100 100.0 % 1.13 [ 0.45, 2.80 ]
Subtotal (95% CI) 100 100 100.0 % 1.13 [ 0.45, 2.80 ]
Total events: 9 (Laxative), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
3 Two days
Mundow 1975 25/100 42/100 100.0 % 0.60 [ 0.39, 0.90 ]
Subtotal (95% CI) 100 100 100.0 % 0.60 [ 0.39, 0.90 ]
Total events: 25 (Laxative), 42 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
4 Three days
Mundow 1975 35/100 26/100 100.0 % 1.35 [ 0.88, 2.06 ]
Subtotal (95% CI) 100 100 100.0 % 1.35 [ 0.88, 2.06 ]
Total events: 35 (Laxative), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
5 Four days
Mundow 1975 27/100 10/100 100.0 % 2.70 [ 1.38, 5.28 ]
Subtotal (95% CI) 100 100 100.0 % 2.70 [ 1.38, 5.28 ]
Total events: 27 (Laxative), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.90 (P = 0.0037)
6 Five days
Mundow 1975 4/100 5/100 100.0 % 0.80 [ 0.22, 2.89 ]
Subtotal (95% CI) 100 100 100.0 % 0.80 [ 0.22, 2.89 ]
0.002 0.1 1 10 500
More in placebo group More in laxative laxative
(Continued . . . )
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(. . . Continued)
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 4 (Laxative), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Chi2 = 20.75, df = 5 (P = 0.00), I2 =76%
0.002 0.1 1 10 500
More in placebo group More in laxative laxative
Analysis 1.11. Comparison 1 Laxative versus placebo, Outcome 11 Number having abdominal cramps.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 11 Number having abdominal cramps
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mundow 1975 1/100 4/100 0.25 [ 0.03, 2.20 ]
Shelton 1980 23/224 6/247 4.23 [ 1.75, 10.19 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laxative Favours placebo
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Analysis 1.12. Comparison 1 Laxative versus placebo, Outcome 12 Adverse effects on the baby.
Review: Interventions for preventing postpartum constipation
Comparison: 1 Laxative versus placebo
Outcome: 12 Adverse effects on the baby
Study or subgroup Laxative Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Loose stools
Shelton 1980 3/126 6/155 75.4 % 0.62 [ 0.16, 2.41 ]
Subtotal (95% CI) 126 155 75.4 % 0.62 [ 0.16, 2.41 ]
Total events: 3 (Laxative), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
2 Diarrhoea
Shelton 1980 2/126 1/155 24.6 % 2.46 [ 0.23, 26.82 ]
Subtotal (95% CI) 126 155 24.6 % 2.46 [ 0.23, 26.82 ]
Total events: 2 (Laxative), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 252 310 100.0 % 0.87 [ 0.26, 2.83 ]
Total events: 5 (Laxative), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 0.97, df = 1 (P = 0.32), I2 =0.0%
0.01 0.1 1 10 100
Favours laxative Favours placebo
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Analysis 2.1. Comparison 2 Laxative alone versus laxative plus bulking agent, Outcome 1 Faecal
incontinence during first 10 postpartum days.
Review: Interventions for preventing postpartum constipation
Comparison: 2 Laxative alone versus laxative plus bulking agent
Outcome: 1 Faecal incontinence during first 10 postpartum days
Study or subgroup Laxative alone
Laxative +
bulking
agent Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Eogan 2007 14/77 23/70 100.0 % 0.55 [ 0.31, 0.99 ]
Total (95% CI) 77 70 100.0 % 0.55 [ 0.31, 0.99 ]
Total events: 14 (Laxative alone), 23 (Laxative + bulking agent)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less laxative alone Less laxative + bulking
A P P E N D I C E S
Appendix 1. Bristol stool form scale
Type Description
1 Separate hard lumps like nuts (difficult to pass)
2 Sausage-shaped but lumpy
3 Like a sausage but with cracks on its surface
4 Like a sausage or snake, smooth and soft
5 Soft blobs with clear-cut edges (passed easily)
6 Fluffy pieces with ragged edges, a mushy stool
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(Continued)
7 Watery, no solid pieces, entirely liquid
Appendix 2. Search terms
The US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) and the World Health Organization International
Clinical Trials Registry platform (ICTRP).
Search terms: constipation AND (postpartum OR postnatal OR “after birth” OR “post delivery”) AND (interventions OR prevent*
OR avert OR avoid).
ForUniversity of Stellenbosch database wewill use the following terms: (postnatalOR “post delivery”ORpostpartum)AND (constipat*
OR hard stool* OR “impacted stool” OR “lumpy stool” OR “rock-like stool”) AND (interventions OR prevent* OR avert OR avoid).
Search terms for ProQuest: (post-delivery OR postpartum OR postnatal OR afterbirth) AND (constipat* OR hard stool* OR rock-
like stool OR lumpy stool) AND (prevent* OR avoid OR interventions).
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have added the primary outcome: Time to first bowel movement. This was not one of the pre-specified outcomes in our protocol
(Turawa 2015).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Postpartum Period; Constipation [∗prevention & control]; Dietary Fiber [∗therapeutic use]; Laxatives [∗therapeutic use]; Perineum
[injuries]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Female; Humans
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